ABBV News
AbbVie Inc.
$294.45
-$0.53(-0.18%)
58
Overall
60
Value
66
Tech
50
Quality
Market Cap
$520.47B
Volume
4.75M
52W Range
$190.75 - $302.93
Target Price
$305.93
ABBV news: the latest AbbVie Inc. headlines, press releases and market updates, newest first.
Latest ABBV News
- AbbVie Crohn’s Disease Study Update Offers Limited Near-Term Stock ImpactTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 12, 2026
- Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), AbbVie (ABBV)TipRanks Newsroom · Nov 10, 2026
- AbbVie Advances New Facial-Line Injection Study as Investors Watch Aesthetic GrowthTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 5, 2026
- AbbVie Updates Early-Stage Drug Interaction Study: What ABBV Investors Should KnowTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 5, 2026
- Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)TipRanks Newsroom · Nov 3, 2026
- AbbVie (ABBV) Receives a Rating Update from a Top AnalystTipRanks Auto-Generated Intelligence Newsdesk · Nov 2, 2026
- Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Agios Pharma (AGIO)TipRanks Newsroom · Nov 2, 2026
- Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Regeneron (REGN) and Stoke Therapeutics (STOK)TipRanks Newsroom · Nov 2, 2026
- AbbVie’s New Phase 1 ABBV-7828 Trial Signals Quiet Pipeline ExpansionTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 29, 2026
- Piper Sandler Reaffirms Their Buy Rating on AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 26, 2026
- Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Parabilis Medicines, Inc. (PBLS) and Kyverna Therapeutics, Inc. (KYTX)TipRanks Newsroom · Oct 26, 2026
- The Week That Was, The Week Ahead: Macro and Markets, October 25Ran Melamed · Oct 25, 2026
- AbbVie Targets Essential Tremor With New Mid-Stage Trial, Adding Depth to Its Neurology PipelineTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 22, 2026
- AbbVie Halts Early-Stage Liver Cancer Combo Trial: What It Means for ABBV InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 21, 2026
- Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- Citi Sticks to Their Hold Rating for AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- Citi Sticks to Their Hold Rating for AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- AbbVie (ABBV) Receives a Buy from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPODavid Craik · Oct 15, 2026
- AbbVie Targets Head and Neck Cancer With New Telisotuzumab Combo TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 13, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABBV | $294.45 | -0.2% | 4.75M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |